Ligand ID: TAC


Drugbank ID:
DB00759
(Tetracycline)


Indication:
Used to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.

Get human targets for TAC in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'TAC' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.59A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6lxt SPIKE PROTEIN S2
(SARS-CoV-2)		5 / 12
LEU A1166
SER B 968
PHE A 970
GLN B 965
ILE A1172
1.69A21.63
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6lze VIRAL PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.60A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU B  30
VAL B  13
CYH B 160
VAL B 157
ILE B 152
1.59A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU C  30
VAL C  13
CYH C 160
VAL C 157
ILE C 152
1.67A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
SER C  10
PRO C   9
VAL A 125
LEU A  30
1.77A9.68

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 7
VAL A 296
LEU A 220
THR A 304
SER A 301
1.76A19.66

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m2n 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU D  30
VAL D  13
CYH D 160
VAL D 157
ILE D 152
1.66A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m2q 3CL PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU D  91
LEU C  20
VAL C  66
LEU D  95
ILE C  68
1.79A19.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 567
SER A 561
VAL A 560
LEU A 663
1.65A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU B  95
LEU A 366
VAL A 335
LEU B  98
VAL A 342
1.70A19.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 6
SER A 681
VAL A 560
THR A 556
SER A 682
1.58A17.19
8.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 146
1.53A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 142
1.61A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP12
(SARS-CoV-2)		5 / 11
LEU A 862
LEU A 883
VAL A 880
CYH A 842
VAL A 435
1.67A12.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP12
NSP8
(SARS-CoV-2)		5 / 11
HIS A 381
LEU A 366
CYH A 563
ILE A 562
VAL B  83
1.70A12.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
VAL A 662
LEU A 351
THR A 531
SER A 564
1.73A17.19

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  56
LEU C  28
VAL C  58
LEU D 103
ILE D 120
1.73A16.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 6
THR A 556
SER A 682
SER A 681
VAL A 560
1.53A8.44
17.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
NSP7
(SARS-CoV-2)		4 / 7
SER C  15
VAL C  12
LEU A 437
ASP A 846
1.60A12.24

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 531
SER A 564
VAL A 662
LEU A 351
1.70A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
SER B 164
VAL B 160
LEU A 388
1.62A11.73

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
LEU A 146
THR A 120
ASP A 211
1.56A17.19

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP12
(SARS-CoV-2)		5 / 11
HIS A 347
CYH A 659
ILE A 632
MET A 629
VAL A 315
1.67A12.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6m71 NSP12
(SARS-CoV-2)		5 / 12
TYR A 122
ILE A 171
TYR A 175
ILE A 145
TYR A 149
1.61A14.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
SER B 164
VAL B 160
LEU A 388
PRO B 183
1.56A19.10

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
SER A 681
VAL A 560
THR A 556
SER A 682
1.51A17.19

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
NSP7
(SARS-CoV-2)		4 / 7
ASP A 846
SER C  15
VAL C  12
LEU A 437
1.58A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6m71 NSP7
(SARS-CoV-2)		5 / 11
LEU C  13
HIS C  36
LEU C  40
LEU C  56
MET C   3
1.73A16.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6m71 NSP12
(SARS-CoV-2)		4 / 7
THR A 556
SER A 682
SER A 681
VAL A 560
1.52A8.44

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 7
THR B  95
PRO B 217
VAL B  62
LEU B 223
1.32A2.57
13.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C 858
ASN C 955
VAL C1008
GLN C1011
ILE C 770
1.64A10.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL A 524
ASN A 394
TYR A 396
TYR A 365
ILE A 358
1.71A12.32
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
THR C 778
ASP C 775
PRO C 863
VAL C 860
1.59A2.57
13.14
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6vww URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
LEU A 346
LEU A 255
ILE A 270
VAL A 276
ILE A 296
1.43A20.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6vxs NSP3
(SARS-CoV-2)		5 / 11
LEU A 126
VAL A  49
LEU A 153
VAL A  35
ILE A  23
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C1063
SER C1051
PHE C 927
GLN C1054
ILE C 882
1.80A10.48
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU B1049
VAL B1065
LEU B 806
ILE B 923
ILE B 931
1.55A9.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 6
SER C 967
ASP B 571
SER C 975
VAL C 976
1.50A2.76
13.42
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 11
LEU A1049
VAL A1065
LEU A 806
ILE A 923
ILE A 931
1.52A9.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
VAL A1133
ASN A1135
ILE A1130
PHE A1089
TYR B 917
1.60A12.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 12
LEU C 518
ARG C 328
PRO C 579
GLN C 564
ILE C 332
1.56A10.48
None
None
None
None
NAG  C1305 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
SER A 274
ASN A  75
PRO A 344
VAL A 276
ILE A 323
1.69A18.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 12
SER B 274
ASN B  75
PRO B 344
VAL B 276
ILE B 323
1.57A19.73
EDO  B 403 (-2.8A)
EDO  B 403 (-4.6A)
None
EDO  B 403 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
SER B 274
ASN B  75
PRO B 344
VAL B 276
ILE B 323
1.55A19.46
EDO  B 403 (-2.8A)
EDO  B 403 (-4.6A)
None
EDO  B 403 (-3.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w4h NSP16
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.58A19.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.46A12.50
18.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.45A18.60
12.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w75 NSP16
(SARS-CoV-2)		5 / 11
LEU C7010
HIS C6984
LEU C6981
LEU C7073
VAL C6965
1.54A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL C7057
LEU C6959
THR C6891
PRO C6860
1.51A17.22
11.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6w75 NSP16
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.79A20.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6w75 NSP16
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.54A21.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w75 NSP16
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.56A11.88
17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w75 NSP16
(SARS-CoV-2)		4 / 7
THR C6891
PRO C6860
VAL C7057
LEU C6959
1.53A11.88
17.22
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6w75 NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.78A21.36
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w75 NSP16
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.55A17.22
11.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
THR B  63
ASP B  61
PRO B  59
VAL B  57
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
VAL B 165
TYR B 112
ILE B 123
PHE B 127
ILE B 151
1.78A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 6
VAL B  57
THR B  63
ASP B  61
PRO B  59
1.76A21.28
8.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 7
VAL B  57
THR B  63
ASP B  61
PRO B  59
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
VAL C 165
TYR C 112
ILE C 123
PHE C 127
ILE C 151
1.67A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		5 / 12
TYR A 251
ILE A 285
TYR A 296
GLU A 263
ILE A 300
1.45A23.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wey NSP3
(SARS-CoV-2)		5 / 12
VAL A 351
ASN A 354
TYR A 356
TYR A 317
PHE A 372
1.52A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wiq NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU B  98
VAL A   6
LEU A  14
ILE B 107
ILE A  39
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wiq NSP8
(SARS-CoV-2)		5 / 12
PRO B 116
ILE B 120
PHE B 147
TYR B 149
ILE B 132
1.30A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wiq NSP8
(SARS-CoV-2)		5 / 12
PRO B 116
VAL B 131
ILE B 120
TYR B 149
TYR B 138
1.65A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wiq NSP8
(SARS-CoV-2)		5 / 12
PRO B 116
ILE B 120
TYR B 149
ILE B 132
TYR B 138
1.64A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wiq NSP8
(SARS-CoV-2)		5 / 11
LEU B 169
VAL B 159
LEU B 128
CYH B 142
ILE B 185
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU D 352
LEU D 339
LEU D 291
ILE D 337
ILE D 357
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU E 352
LEU E 339
LEU E 291
ILE E 337
ILE E 357
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU B 352
LEU B 339
LEU B 291
ILE B 337
ILE B 357
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		5 / 11
LEU F 352
LEU F 339
LEU F 291
ILE F 337
ILE F 357
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
THR C6891
PRO C6860
VAL C7057
LEU C6959
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
VAL B4295
LEU A6834
SER A6872
ASP A6873
1.42A
None
None
SAH  A7102 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
VAL D4295
LEU C6834
SER C6872
ASP C6873
1.44A
None
None
SAH  C7102 (-4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU C7010
HIS C6984
LEU C6981
LEU C7073
VAL C6965
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL C7057
LEU C6959
THR C6891
PRO C6860
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
SER C6872
ASP C6873
VAL D4295
LEU C6834
1.46A
SAH  C7102 (-4.7A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
ILE A6925
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 7
SER A6872
ASP A6873
VAL B4295
LEU A6834
1.46A
SAH  A7102 ( 4.6A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wkq NSP16
(SARS-CoV-2)		4 / 7
THR C6891
PRO C6860
VAL C7057
LEU C6959
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wkq NSP16
(SARS-CoV-2)		4 / 7
VAL C7057
LEU C6959
THR C6891
PRO C6860
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wkq NSP16
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wkq NSP16
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wkq NSP16
(SARS-CoV-2)		5 / 11
LEU C7010
HIS C6984
LEU C6981
LEU C7073
VAL C6965
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wkq NSP16
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6wkq NSP16
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
THR A 196
ASP A 324
SER A 274
LEU A 255
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
THR B 196
ASP B 324
SER B 274
LEU B 255
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
SER B 274
LEU B 201
THR B 196
ASP B 324
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
SER B 274
LEU B 255
THR B 196
ASP B 324
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
THR A 196
ASP A 324
SER A 274
LEU A 201
1.54A
None
None
None
EDO  A 405 (-4.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
SER B 274
ASN B  75
PRO B 344
VAL B 276
ILE B 323
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
THR B 196
ASP B 324
SER B 274
LEU B 201
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
SER A 274
LEU A 201
THR A 196
ASP A 324
1.58A
None
EDO  A 405 (-4.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 7
SER A 274
LEU A 255
THR A 196
ASP A 324
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 11
SER A 274
ASN A  75
PRO A 344
VAL A 276
ILE A 323
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A 268
LEU A 250
VAL A 202
LEU A 287
ILE A 200
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU B 126
VAL B  16
LEU B 160
MET B 171
ILE B  18
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU C  83
HIS C  86
LEU C  88
LEU C  43
ILE C  23
1.71A
None
None
None
None
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  83
HIS A  86
LEU A  88
LEU A  43
ILE A  23
1.70A
None
None
None
None
APR  A 201 (-4.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU C 126
VAL C  16
LEU C 160
MET C 171
ILE C  18
1.78A
APR  C 201 (-4.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU C 126
VAL C  49
LEU C 153
VAL C  35
ILE C  23
1.79A
APR  C 201 (-4.9A)
APR  C 201 (-3.8A)
None
None
APR  C 201 (-3.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2TRT_A_TACA222_1
(TETRACYCLINE
REPRESSOR CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
THR A6891
PRO A6860
VAL A7057
LEU A6959
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
LEU A7010
HIS A6984
LEU A6981
LEU A7073
VAL A6965
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2VKE_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 11
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
VAL A7057
LEU A6959
THR A6891
PRO A6860
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 12
ASN A6994
PHE A6991
PRO A6810
GLN A6801
ILE A7035
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP8
(SARS-CoV-2)		5 / 11
LEU D 169
VAL D 159
LEU D 128
CYH D 142
ILE D 185
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wqd NSP7
NSP8
(SARS-CoV-2)		4 / 7
VAL A  53
LEU A  71
SER B 151
ASP B 101
1.58A
EDO  B 302 ( 4.8A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU A  13
VAL A  58
LEU B 128
ILE A  39
ILE B 119
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wqd NSP8
(SARS-CoV-2)		5 / 12
PRO B 116
ILE B 120
PHE B 147
TYR B 149
ILE B 132
1.38A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  13
VAL C  58
LEU D 128
ILE C  39
ILE D 119
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  40
HIS C  36
LEU C  14
MET D  87
VAL A  11
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wqd NSP7
NSP8
(SARS-CoV-2)		4 / 7
SER B 151
ASP B 101
VAL A  53
LEU A  71
1.57A
None
None
EDO  B 302 ( 4.8A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wqd NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
PHE D 147
TYR D 149
ILE D 132
1.38A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqd NSP8
(SARS-CoV-2)		5 / 11
LEU B 169
VAL B 159
LEU B 128
CYH B 142
ILE B 185
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wqd NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
VAL D 131
ILE D 120
TYR D 149
TYR D 138
1.72A20.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 7
SER A 180
PRO A 240
VAL A 205
LEU A 120
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 7
VAL A 205
LEU A 120
SER A 180
PRO A 240
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 12
TYR A 251
ILE A 285
TYR A 296
GLU A 263
ILE A 300
1.43A22.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6wrh PEPTIDASE C16
(SARS-CoV-2)		5 / 11
LEU A 162
LEU A 113
CYH A 155
MET A 169
VAL A 165
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6y2g REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.54A20.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU A  56
LEU A  28
VAL A  58
LEU B 103
ILE B 120
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
VAL C  53
LEU C  71
SER D 151
ASP D 101
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
SER B 151
ASP B 101
VAL A  53
LEU A  71
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU C  13
VAL C  58
LEU D 128
ILE C  39
ILE D 119
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
VAL A  53
LEU A  71
SER B 151
ASP B 101
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
PHE D 147
TYR D 149
ILE D 132
1.29A21.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU D 169
VAL D 159
LEU D 128
CYH D 142
ILE D 185
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 7
SER D 151
ASP D 101
VAL C  53
LEU C  71
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 11
LEU B 169
VAL B 159
LEU B 128
CYH B 142
ILE B 185
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		5 / 12
PRO B 116
ILE B 120
PHE B 147
TYR B 149
ILE B 132
1.37A21.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
PRO A  98
VAL A  96
ASN A  37
ILE A 106
ILE A 131
1.52A19.34
None
None
None
None
EDO  A 202 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		5 / 12
PRO E  98
VAL E  96
ASN E  37
ILE E 106
ILE E 131
1.53A19.34
None
None
None
None
EPE  E 202 (-3.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bqy MAIN PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 7
VAL A 398
LEU A 329
THR B 123
PRO B 121
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 146
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 7
PRO B 183
SER B 164
VAL B 160
LEU A 388
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7btf NSP8
(SARS-CoV-2)		5 / 11
LEU D 169
VAL D 159
LEU D 128
CYH D 142
ILE D 185
1.53A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
(SARS-CoV-2)		4 / 7
THR A 531
SER A 564
VAL A 662
LEU A 351
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
(SARS-CoV-2)		4 / 7
SER A 318
VAL A 315
LEU A 663
PRO A 461
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 7
ASP A 846
SER C  15
VAL C  12
LEU A 437
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7btf NSP12
(SARS-CoV-2)		5 / 11
LEU A 862
LEU A 883
VAL A 880
CYH A 842
VAL A 435
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
(SARS-CoV-2)		4 / 7
PRO A 461
SER A 318
VAL A 315
LEU A 663
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7btf NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
PHE D 147
TYR D 149
ILE D 132
1.26A22.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7btf NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
TYR D 149
ILE D 132
TYR D 138
1.50A22.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7btf NSP12
(SARS-CoV-2)		5 / 12
TYR A 122
ILE A 171
TYR A 175
ILE A 145
TYR A 149
1.68A14.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 7
THR B 123
PRO B 121
VAL A 398
LEU A 329
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7btf NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU A 361
VAL A 359
ASN A 534
CYH B 114
VAL A 342
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7btf NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  35
LEU C  28
VAL C  58
LEU D 122
ILE D 120
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		5 / 11
LEU A  30
VAL A  13
CYH A 160
VAL A 157
ILE A 152
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
THR A 531
SER A 564
VAL A 662
LEU A 351
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 7
THR B 123
PRO B 121
VAL A 398
LEU A 329
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP12
(SARS-CoV-2)		5 / 11
LEU A 862
LEU A 883
VAL A 880
CYH A 842
VAL A 435
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
PHE D 147
TYR D 149
ILE D 132
1.36A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
ILE D 120
TYR D 149
ILE D 132
TYR D 138
1.70A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 146
1.24A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 142
1.43A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
SER A 672
VAL A 398
THR A 393
ASP A 390
1.54A17.28
8.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP12
(SARS-CoV-2)		5 / 11
HIS A 347
CYH A 659
ILE A 632
MET A 629
VAL A 315
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU A 361
VAL A 359
ASN A 534
CYH B 114
VAL A 342
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP7
(SARS-CoV-2)		4 / 7
SER C  25
VAL C  22
LEU C  55
SER C  26
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP12
(SARS-CoV-2)		5 / 11
LEU A 142
LEU A 212
CYH A 151
VAL A 182
ILE A 244
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
LEU A 146
THR A 120
ASP A 211
1.27A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
VAL D 131
ILE D 120
PHE D 147
TYR D 149
1.65A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4B3A_A_TACA222_1
(TETRACYCLINE
REPRESSOR PROTEIN
CLASS D)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
LEU A 575
SER A 578
PHE A 480
ILE A 589
SER A 692
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP7
NSP8
(SARS-CoV-2)		5 / 11
LEU C  35
LEU C  28
VAL C  58
LEU D 122
ILE D 120
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
SER A 835
ASP A 833
PRO A 832
VAL A 880
1.73A8.44
17.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv1 NSP7
(SARS-CoV-2)		5 / 11
LEU C  13
HIS C  36
LEU C  40
LEU C  56
MET C   3
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
SER A 672
VAL A 398
THR A 393
ASP A 390
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
SER A 318
VAL A 315
LEU A 663
PRO A 461
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP8
(SARS-CoV-2)		5 / 12
PRO D 116
VAL D 131
ILE D 120
TYR D 149
TYR D 138
1.52A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv1 NSP12
(SARS-CoV-2)		5 / 12
TYR A 122
ILE A 171
TYR A 175
ILE A 145
TYR A 149
1.76A14.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 6
VAL A 557
THR A 687
SER A 681
ASP A 684
1.78A17.28
8.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv1 NSP12
(SARS-CoV-2)		4 / 7
PRO A 461
SER A 318
VAL A 315
LEU A 663
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 531
SER A 564
VAL A 662
LEU A 351
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
VAL A 330
LEU B  98
ILE A 539
MET A 666
ILE B 120
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
VAL A 398
LEU A 329
THR B 123
PRO B 121
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
THR A 687
SER A 681
ASP A 684
VAL A 557
1.79A8.44
17.28
F86  P 102 (-3.6A)
None
None
U  T  10 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU A 387
LEU A 401
LEU B 122
ILE A 539
ILE B 120
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
(SARS-CoV-2)		5 / 11
LEU A 142
LEU A 212
CYH A 151
VAL A 182
ILE A 244
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU A 361
VAL A 359
ASN A 534
CYH B 114
VAL A 342
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 687
SER A 681
ASP A 684
VAL A 557
1.74A
F86  P 102 (-3.6A)
None
None
U  T  10 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
VAL A 182
LEU A 146
THR A 120
ASP A 211
1.22A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
SER A 681
VAL A 560
THR A 556
SER A 682
1.67A
None
U  T  10 ( 4.6A)
None
U  T  10 (-2.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
SER A 681
VAL A 560
THR A 556
SER A 682
1.71A17.28
8.44
None
U  T  10 ( 4.6A)
None
U  T  10 (-2.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3Q5P_A_TACA7101_1
(MULTIDRUG-EFFLUX
TRANSPORTER 1
REGULATOR)		7bv2 NSP12
(SARS-CoV-2)		5 / 12
TYR A 122
ILE A 171
TYR A 175
ILE A 145
TYR A 149
1.70A14.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
THR B 123
PRO B 121
VAL A 398
LEU A 329
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 556
SER A 682
SER A 681
VAL A 560
1.68A
None
U  T  10 (-2.9A)
None
U  T  10 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
SER A 318
VAL A 315
LEU A 663
PRO A 461
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
NSP8
(SARS-CoV-2)		5 / 11
LEU B  91
LEU B  98
VAL A 341
LEU A 366
ILE A 333
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP7
(SARS-CoV-2)		5 / 11
LEU C  13
HIS C  36
LEU C  40
LEU C  56
MET C   3
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_H_TACH4888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
VAL A 557
THR A 687
SER A 681
ASP A 684
1.77A
 U  T  10 ( 4.6A)
F86  P 102 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2UXO_B_TACB1211_1
(HTH-TYPE
TRANSCRIPTIONAL
REGULATOR TTGR)		7bv2 NSP12
(SARS-CoV-2)		5 / 11
LEU A 862
LEU A 883
VAL A 880
CYH A 842
VAL A 435
1.77A
 U  P  17 ( 4.9A)
None
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_J_TACJ5888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
THR A 556
SER A 682
SER A 681
VAL A 560
1.68A8.44
17.28
None
U  T  10 (-2.9A)
None
U  T  10 ( 4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
PRO A 461
SER A 318
VAL A 315
LEU A 663
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 142
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_F_TACF3888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 7
THR A 120
ASP A 211
VAL A 182
LEU A 146
1.19A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2HDN_L_TACL6888_1
(ELONGATION FACTOR
EF-TU)		7bv2 NSP12
(SARS-CoV-2)		4 / 6
VAL A 557
THR A 687
SER A 681
ASP A 684
1.69A17.28
8.44
 U  T  10 ( 4.6A)
F86  P 102 (-3.6A)
None
None